Abstract
Severe asthma constitutes a serious health burden with significant morbidity and socio-economic costs. The development and introduction of new biologics targeting type 2 in-flammation changed the paradigm for management of severe asthma and initiated a biological era. These changes impose a challenge to clinicians in managing difficult-to-treat and severe asthma. To understand the characteristics and heterogeneity of severe asthma and to develop a better strategy to manage it, the Korean Academy of Asthma, Allergy and Clinical Immunology, Working Group on Severe Asthma, has organized the Korean Severe Asthma Registry (KoSAR). In this review, we describe the challenges of severe asthma management regarding diagnosis, disease burden, heterogeneity, guidelines, and organization of severe asthma clinics. This review also examines the current global activities of national and regional registries and study groups. In addition, we present the KoSAR vision and organization and describe the findings of KoSAR in comparison with those of other countries.
Original language | English |
---|---|
Pages (from-to) | 249-260 |
Number of pages | 12 |
Journal | Korean Journal of Internal Medicine |
Volume | 37 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2022 |
Bibliographical note
Funding Information:This work was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HC19C0318). The authors thank the investigators, clinical research coordinators, and participants for their time and efforts in the KoSAR.
Publisher Copyright:
© 2022 The Korean Association of Internal Medicine.
Keywords
- Biological products
- Real world
- Registries
- Severe asthma